Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	14.15B
Revenue (ttm)	990.96M
Net Income (ttm)	407.92M
Shares Out	87.60M
EPS (ttm)	4.61
PE Ratio	35.06
Forward PE	28.99
Dividend	4.65 (2.88%)
Ex-Dividend Date	Apr 30, 2025

Volume	123,957
Average Volume	373,015
Open	159.50
Previous Close	160.50
Day's Range	159.50 - 162.50
52-Week Range	130.45 - 188.00
Beta	0.43
RSI	39.72
Earnings Date	Nov 12, 2025

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2024, TPEX:6712's revenue was 933.81 million, an increase of 23.13% compared to the previous year's 758.39 million. Earnings were 367.25 million, a decrease of -31.91%.